This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
QP-Lung®
Refining lung cancer heterogeneity analysis and predicting clinical endpoints through SoC CT acquisitions
Many therapeutic decisions in lung cancer are today based on techniques which provide information about the tumor mutational status from next generation sequencing (NGS) and the PD-L1 fraction of the tissue through immunohistochemistry (IHC), among others. Quibim is developing a new solution to work in combination with existing techniques to classify tumor mutational status, predict response to immune checkpoint inhibitors and overall survival from the analysis of the baseline CT scan.